HB Wealth Management LLC Buys 185 Shares of Solventum Corporation $SOLV

HB Wealth Management LLC increased its position in Solventum Corporation (NYSE:SOLV) by 5.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,463 shares of the company’s stock after acquiring an additional 185 shares during the quarter. HB Wealth Management LLC’s holdings in Solventum were worth $263,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Rossby Financial LCC purchased a new stake in Solventum in the 1st quarter worth approximately $25,000. Strengthening Families & Communities LLC increased its holdings in shares of Solventum by 376.8% in the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock worth $25,000 after purchasing an additional 260 shares during the period. Hara Capital LLC purchased a new stake in shares of Solventum in the first quarter worth $38,000. Smartleaf Asset Management LLC raised its position in shares of Solventum by 193.4% in the first quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock worth $40,000 after buying an additional 352 shares in the last quarter. Finally, Costello Asset Management INC bought a new stake in Solventum during the first quarter valued at $42,000.

Solventum Price Performance

SOLV opened at $73.88 on Tuesday. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The stock has a 50-day moving average price of $72.81 and a 200-day moving average price of $72.16. The firm has a market cap of $12.81 billion, a PE ratio of 34.20, a P/E/G ratio of 3.01 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to analyst estimates of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. Solventum’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the business earned $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Sell-side analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on SOLV shares. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $80.00 to $103.00 in a research note on Tuesday, July 15th. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. Weiss Ratings restated a “hold (c-)” rating on shares of Solventum in a research report on Saturday, September 27th. Zacks Research raised shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. Finally, Wells Fargo & Company raised their price target on Solventum from $79.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $84.60.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.